Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement.

Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement.

Genentech, a member of the Roche Group, announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo ® 100 mg/mL for the treatment of diabetic macular edema and ...

Genentech, a member of the Roche Group announced today that the U.S. Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic retinopathy, a potentially ...

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness. Business Wire . Tue, Feb 4, 2025, 11:45 AM 11 min read.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for ...

Genentech plans to reintroduce Susvimo for the treatment of wet age-related macular degeneration. The company is also investigating other medicines for use with the port delivery system. Nearly 2 ...

Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release. The ...

This month, Genentech announced a voluntary recall of the ranibizumab injection (SUSVIMO) ocular implant and associated insertion tool. SUSVIMO, which provides continuous administration of the ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo ® (ranibizumab injection) 100 ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for ...

FDA Approves Genentech’s Susvimo for Diabetic Retinopathy. May 22, 2025 11:45 AM ET Roche Holding AG (RHHBY) ...